Phase I Study of Apatinib Plus Gefitinib as First-Line Therapy in Patients with EGFR Mutant Advanced NonSmall Cell Lung Cancer

被引：2
|
作者：
Zhao, H. [1 ]
Zhang, Z. [2 ]
Li, S. [1 ]
Fang, W. [3 ]
Ma, Y. [1 ]
Zhang, Y. [1 ]
Yang, Y. [2 ]
Luo, F. [2 ]
Huang, Y. [2 ]
Zhang, L. [2 ]
机构：
[1] Sun Yat Sen Univ, Canc Ctr, Dept Clin Res, Guangzhou, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Canc Ctr, Dept Med Oncol, Guangzhou, Guangdong, Peoples R China
[3] Sun Yat Sen Univ, Med Oncol, Guangzhou, Guangdong, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
non-small cell lung cancer; gefitinib; Apatinib;
D O I：
10.1016/j.jtho.2018.08.666
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.01-109
引用
收藏
页码：S506 / S506
页数：1
相关论文
共 50 条
  • [1] Pemetrexed/carboplatin plus gefitinib as a first-line treatment for EGFR-mutant advanced nonsmall cell lung cancer: a Bayesian network meta-analysis
    Zhang, Zhonghan
    Zeng, Kangmei
    Zhao, Shen
    Zhao, Yuanyuan
    Hou, Xue
    Luo, Fan
    Lu, Feiteng
    Zhang, Yaxiong
    Zhou, Ting
    Ma, Yuxiang
    Yang, Yunpeng
    Fang, Wenfeng
    Huang, Yan
    Zhang, Li
    Zhao, Hongyun
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2019, 11
  • [2] Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC: The Phase III ACTIVE Study (CTONG1706)
    Zhao, Hongyun
    Yao, Wenxiu
    Min, Xuhong
    Gu, Kangsheng
    Yu, Guohua
    Zhang, Zhonghan
    Cui, Jiuwei
    Miao, Liyun
    Zhang, Li
    Yuan, Xia
    Fang, Yong
    Fu, Xiuhua
    Hu, Chengping
    Zhu, Xiaoli
    Fan, Yun
    Yu, Qitao
    Wu, Gang
    Jiang, Ou
    Du, Xiuping
    Liu, Jiwei
    Gu, Wei
    Hou, Zhiguo
    Wang, Quanren
    Zheng, Rongrong
    Zhou, Xianfeng
    Zhang, Li
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (09) : 1533 - 1546
  • [3] The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706)
    Zhang, Zhonghan
    Luo, Fan
    Zhang, Yang
    Ma, Yuxiang
    Hong, Shaodong
    Yang, Yunpeng
    Fang, Wenfeng
    Huang, Yan
    Zhang, Li
    Zhao, Hongyun
    [J]. CANCER COMMUNICATIONS, 2019, 39 (01):
  • [4] Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer
    Wu, Jenn-Yu
    Shih, Jin-Yuan
    Yang, Chih-Hsin
    Chen, Kuan-Yu
    Ho, Chao-Chi
    Yu, Chong-Jen
    Yang, Pan-Chyr
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2010, 126 (01) : 247 - 255
  • [5] Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a first-line treatment for advanced EGFR-mutant non-small cell lung cancer
    Zhang, Zhonghan
    Zhang, Yang
    Luo, Fan
    Ma, Yuxiang
    Fang, Wenfeng
    Zhan, Jing
    Li, Su
    Yang, Yunpeng
    Zhao, Yuanyuan
    Hong, Shaodong
    Zhou, Ting
    Zhang, Yaxiong
    Zhao, Shen
    Huang, Yan
    Zhao, Hongyun
    Zhang, Li
    [J]. CLINICAL AND TRANSLATIONAL MEDICINE, 2020, 10 (02):
  • [6] First-Line Gemcitabine Plus Cisplatin in Nonsmall Cell Lung Cancer Patients
    Li, Ying
    Wang, Lin Run
    Chen, Jian
    Lou, Yan
    Zhang, Guo Bing
    [J]. DISEASE MARKERS, 2014, 2014
  • [7] Anlotinib with gefitinib as first-line therapy in advanced non-small cell lung cancer harboring EGFR mutations: A phase II study
    Ji, Y.
    Wang, X.
    Lou, Z.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S979 - S979
  • [8] Gefitinib versus erlotinib as first-line treatment in EGFR mutant advanced lung adenocarcinoma
    Shee, Chai Chee
    Kin, Liam Chong
    Kek, Pang Yong
    Siong, Kow Keng
    Ern, Poh Mau
    Kuan, Wong Chee
    Liang, Tan Jiunn
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [9] A multicenter, randomized, double-blind, placebo-controlled phase III study of apatinib or placebo plus gefitinib as first-line treatment in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC)
    Zhao, Hongyun
    Zhang, Zhonghan
    Luo, Fan
    Ma, Yuxiang
    Fang, Wenfeng
    Yang, Yunpeng
    Zhang, Yang
    Huang, Yan
    Zhang, Li
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] First-Line Osimertinib in Asian Patients with Advanced EGFR-Mutant Lung Cancer
    Tan, W.
    Chua, B.
    Yin, D.
    Tan, S. H.
    Tan, D.
    Ang, M.
    Kanesvaran, R.
    Jain, A.
    Rajasekaran, T.
    Lai, G.
    Toh, C. K.
    Tan, E.
    Ng, Q. S.
    Lim, W.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S607 - S607
12345